SCHEMBL16631519

SCHEMBL16631519

Cc1cc2cc(C)c(=O)nc-2[nH]c1F

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TNKS O95271 5/20 0.35
TNKS2 Q9H2K2 5/20 0.35
BRD4 O60885 4/20 0.35
PARP1 P09874 4/20 0.35
GAA P10253 3/20 0.35
MAPT P10636 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
ALOX5 P09917 1/20 0.34
MGAM O43451 2/20 0.33
SI P14410 2/20 0.33
MGAM2 Q2M2H8 2/20 0.33
MAPK1 P28482 1/20 0.33
KCNH2 Q12809 2/20 0.33
GUSB P08236 1/20 0.33
NPBWR1 P48145 1/20 0.33
AMY1A P0DUB6 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18081931 0.89 TNKS2 (0.34) TNKSTNKS2BRD4PARP1GAA
SCHEMBL18080459 0.84 TRPV1 (0.34) TNKSTNKS2BRD4PARP1GAA
SCHEMBL16631918 0.82 SLC9A1 (0.35) TNKSTNKS2BRD4PARP1GAA
SCHEMBL16631520 0.81 SMPD3 (0.38) TNKSTNKS2BRD4PARP1GAA
SCHEMBL16631412 0.79 TNKS2 (0.39) TNKSTNKS2PARP1GAAMAPT
SCHEMBL16631706 0.78 NR1I3 (0.36) TNKSTNKS2BRD4PARP1GAA
SCHEMBL18081755 0.77 HPGD (0.36) TNKSTNKS2BRD4PARP1GAA
SCHEMBL16631454 0.77 TNKS (0.34) TNKSTNKS2PARP1GAAMAPT
SCHEMBL16631364 0.75 MGAM (0.35) TNKSTNKS2GAAPARP2ALOX5
SCHEMBL16631931 0.75 PARP1 (0.32) TNKSTNKS2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 TNKS 162/4885TNKS2 183/4885BRD4 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.